A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany lub przerzutowy nowotwór litego z mutacją genu SMARCA4
- •Dla raka płuca: nowotwór nie poddający się standardowemu leczeniu miejscowemu lub nowotwór z przerzutami z mutacją SMARCA4
- •Dla innych typów nowotworów: przerzutowy nowotwór z mutacją SMARCA4
- •Ukończone wszystkie standardowe terapie lub pacjent je odrzuca, albo brak dostępnego standardowego leczenia
- •Wymierny nowotwór (możliwość oceny wielkości guza)
- •Dobry ogólny stan zdrowia (wynik ECOG 0 lub 1)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (33)
UCLA
Santa Monica, United States
University of Colorado Health Hospital
Aurora, United States
Sarah Cannon Research Institute at HealthOne
Denver, United States
Florida Cancer Specialists ORLANDO/DDU
Lake Mary, United States
University of Miami
Miami, United States
University of Chicago
New Lenox, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Columbia University Medical Center
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Ohio State University Hospital
Columbus, United States
Sarah Cannon Research Institute
Nashville, United States
SCRI Oncology Partners
Nashville, United States
Vanderbilt-Ingram Cancer Center
Nashville, United States
MD Anderson Cancer Center
Houston, United States
USO-Virginia Cancer Specialists, PC
Fairfax, United States
Medical College of Wisconsin
Milwaukee, United States
Institut Bergonie
Bordeaux, France
Institut Curie
Paris, France
Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
Villejuif, France
Charite-Universitatsmedizin Berlin
Berlin, Germany
Universitaetsklinikum Essen
Essen, Germany
Krankenhaus Nordwest
Frankfurt am Main, Germany
National Cancer Center Hospital
Chūōku, Japan
National Cancer Center Hospital East
Kashiwa, Japan
The Cancer Institute Hospital of JFCR
Kōtō City, Japan
Shizuoka Cancer Center
Nagaizumi-cho,Sunto-gun, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
National Cancer Center
Ilsandong-gu, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.